Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10909727 | Leukemia Research | 2005 | 11 Pages |
Abstract
In 8 of 12 patients (66.6%), B-CLL cells in vitro constitutively produced TNFα and exerted a TNFα-mediated cytotoxicity, evaluated in an 18-h 51Cr release assay, against the TNFα-sensitive Jurkat, U937 and K562 cell lines but not against the TNFα-resistant Raji cell line. Involvement of TNFα in B-CLL cell cytotoxicity is demonstrated by the fact that anti-TNFα antibodies strongly inhibited it and supernatants of cytotoxic cultures contained TNFα and mediated a completely TNFα-dependent cytotoxicity. When the cytotoxic B-CLL cells were stimulated with interleukin (IL)-2 plus IL-12, there was increased TNFα mRNA expression, TNFα production and TNFα-mediated cytotoxicity. All eight patients with cytotoxic leukemic cells had progressive disease and six of these also expressed high levels of ZAP-70 protein. In the other four patients (33.3%), B-CLL cells did not produce TNFα in vitro and were not cytotoxic, either spontaneously or after IL-2 plus IL-12 stimulation. Of these four patients, three had stable disease and one had progressive disease. The patient with progressive disease and one of the three with stable disease expressed low levels of ZAP-70 protein. We conclude that a group of B-CLL patients with progressive disease have leukemic B cells able to exert in vitro a TNFα-mediated cytotoxicity, which is modulated by cytokines.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Emanuela Rosati, Rita Sabatini, Antonio Tabilio, Mauro Di Ianni, Andrea Bartoli, Pierfrancesco Marconi,